How should I further manage hypertension in an 84‑year‑old female already on atenolol 50 mg, hydrochlorothiazide 12.5 mg, and lisinopril 40 mg?

Management of Uncontrolled Hypertension in an 84-Year-Old on Triple Therapy

Replace atenolol with a calcium channel blocker (amlodipine 5-10 mg daily) while continuing lisinopril 40 mg and hydrochlorothiazide 12.5 mg, as beta-blockers are not first-line agents for hypertension in the elderly and this patient's current regimen lacks the preferred ACE inhibitor/ARB + calcium channel blocker + thiazide combination. 1

Rationale for Medication Adjustment

Why Remove Atenolol

• Beta-blockers are not recommended as first-line therapy for hypertension unless there are compelling indications such as angina, post-myocardial infarction, heart failure with reduced ejection fraction, or heart rate control needs 1
• The 2024 ESC guidelines explicitly state that ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, and thiazides/thiazide-like diuretics have demonstrated the most effective reduction of BP and cardiovascular events and are recommended as first-line treatments 1
• Atenolol can be increased to 100 mg daily per FDA labeling, but increasing beyond this is unlikely to produce further benefit 2
• In elderly patients, atenolol requires cautious dosing due to renal excretion concerns 2

Optimal Three-Drug Combination

• The preferred three-drug combination is a RAS blocker (ACE inhibitor or ARB) with a dihydropyridine calcium channel blocker and a thiazide/thiazide-like diuretic, preferably in a single-pill combination 1
• This patient already has two components (lisinopril + HCTZ) but lacks the calcium channel blocker, which should replace the beta-blocker 1
• Research confirms that ACE inhibitor + calcium channel blocker combinations are as effective as ACE inhibitor + diuretic combinations when added to existing therapy 3

Blood Pressure Target Considerations

Age-Appropriate Targets

• For most adults, including those over 80 years, the 2024 ESC guidelines recommend targeting systolic BP of 120-129 mmHg if well tolerated 1
• This represents a shift from older guidelines: the 2017 ACP/AAFP guideline recommended <150 mmHg for adults ≥60 years (strong recommendation) or <140 mmHg for those with stroke/TIA history or high cardiovascular risk (weak recommendations) 4
• The 2025 AHA/ACC guideline supports more intensive BP control in older adults who are healthy to mildly frail, with greater absolute cardiovascular benefit in adults ≥80 years compared to those 60-79 years 5, 6

Critical Assessment Needed

Before intensifying therapy, evaluate:

• Functional status and frailty level: Benefits of intensive therapy appear non-existent or reversed with moderate to marked frailty 6
• Cognitive function: Benefits diminish when cognitive function is below roughly the 25th percentile 6
• Orthostatic hypotension: Check standing BP after 2 minutes, as this is an exception to consider for intensive targets 1
• Renal function: Atenolol requires dose adjustment in severe renal impairment; assess creatinine clearance 2

Specific Medication Recommendations

Calcium Channel Blocker Addition

• Start amlodipine 5 mg daily, which can be titrated to 10 mg if needed 1
• Dihydropyridine calcium channel blockers are particularly effective for isolated systolic hypertension common in elderly patients 7
• Monitor for peripheral edema, dizziness, and headache (common CCB adverse effects) 4

Optimize Current Medications

• Lisinopril 40 mg is at the higher end of dosing; this is appropriate and should be continued 1
• HCTZ 12.5 mg is appropriate for elderly patients; the FDA label recommends starting with the lowest dose (12.5 mg) in elderly patients and using 12.5 mg increments if further titration needed 8
• Consider switching to a single-pill combination if available, as this improves adherence 1

Monitoring and Safety

Key Adverse Effects to Monitor

• Hypotension and syncope risk increases with lower BP targets 4
• Electrolyte disturbances (hypokalemia, hyponatremia) from thiazide diuretics 4
• Hyperkalemia from ACE inhibitor, especially with declining renal function 4
• Renal function decline: Monitor creatinine and eGFR, particularly given age and ACE inhibitor use 4

Withdrawal Considerations

• Do not abruptly discontinue atenolol; taper over 1-2 weeks to avoid rebound hypertension or tachycardia, even though it's being replaced 2
• If adverse effects occur with the new regimen, target systolic BP that is "as low as reasonably achievable" (ALARA principle) rather than abandoning treatment 1

Alternative Approach if Beta-Blocker Must Continue

If there are compelling indications for beta-blocker continuation (angina, prior MI, heart failure):

• Add amlodipine 5-10 mg to the current regimen as a fourth agent 1
• Beta-blockers can be combined with other major BP-lowering drug classes when compelling indications exist 1
• Research demonstrates that atenolol combined with HCTZ and ACE inhibitors is effective and well-tolerated in elderly patients 9, 10

Maintain BP-lowering treatment lifelong, even beyond age 85, if well tolerated 1